SCHEMBL1542633

SCHEMBL1542633

COc1c(C(=O)c2cccc(F)c2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.46
RELA Q04206 1/20 0.37
TUBB4A P04350 6/20 0.37
TUBB P07437 6/20 0.37
TUBA3C P0DPH7 6/20 0.37
TUBA1B P68363 6/20 0.37
TUBA4A P68366 6/20 0.37
TUBB4B P68371 6/20 0.37
TUBB3 Q13509 6/20 0.37
TUBB2A Q13885 6/20 0.37
TUBB8 Q3ZCM7 6/20 0.37
TUBA3E Q6PEY2 6/20 0.37
TUBA1A Q71U36 6/20 0.37
TUBA1C Q9BQE3 6/20 0.37
TUBB6 Q9BUF5 6/20 0.37
TUBB2B Q9BVA1 6/20 0.37
TUBB1 Q9H4B7 6/20 0.37
KMT2A Q03164 1/20 0.35
CD274 Q9NZQ7 1/20 0.35
NPC1 O15118 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1543290 0.92 CYP3A4 (0.47) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1543014 0.90 CYP3A4 (0.47) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1543192 0.89 CYP3A4 (0.47) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1542980 0.89 CYP3A4 (0.49) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1542920 0.88 CYP3A4 (0.46) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1542836 0.88 CYP3A4 (0.46) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1542483 0.85 CYP3A4 (0.44) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1542781 0.85 CYP3A4 (0.48) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1543057 0.85 CYP3A4 (0.48) CYP3A4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1543061 0.83 CYP3A4 (0.51) CYP3A4TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885RELA 266/4885TUBB4A 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.